NUFORMIX PLC

AGM Information • Sep 10, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8767L

Nuformix PLC

10 September 2019

10th September 2019

Nuformix plc

("Nuformix" or "the Group"),

Result of Annual General Meeting

The Annual General Meeting of Nuformix plc was held on 10th September 2019 at 1.00pm, at the offices of Shakespeare Martineau LLP, 60 Gracechurch Street, London, EC3V 0HR.

As announced this morning resolution 7 was withdrawn from the meeting. The Directors of the Company wish to announce that all other resolutions put to shareholders were duly passed and approved on a show of hands at the meeting.  The results of the proxy voting position received in advance of the meeting are reported below:

	Resolution	Ordinary/ Special	For		Against		Total votes cast
			No. of votes	%	No. of votes	%
1	To receive the annual report and accounts for the year ended 31 March 2019	Ordinary	121,471,999	100	0	0	121,471,999
2	To approve the Annual Report on Remuneration	Ordinary	121,413,979	100	0	0	121,413,979
3	To re-appoint David Tapolczay as a director	Ordinary	121,465,547	100	0	0	121,465,547
4	To re-appoint Daniel Gooding as a director	Ordinary	121,471,999	100	0	0	121,471,999
5	To re-appoint Joanne Holland as a director	Ordinary	121,465,547	100	0	0	121,465,547
6	To re-appoint John Lidgey as a director	Ordinary	83,841,906	99.85	123,641	0.15	83,965,547
7	To re-appoint Kirk Siderman-Wolter as a director	Ordinary	Withdrawn
8	To re-Christopher Blackwell as a director	Ordinary	121,465,547	100	0	0	121,465,547
9	To re-appoint haysmacintyre as auditor	Ordinary	121,465,547	100	0	0	121,465,547
10	To authorise the Directors to determine the auditor's fees.	Ordinary	121,465,547	100	0	0	121,465,547
11	To authorise the Directors to allot shares.	Ordinary	121,471,999	100	0	0	121,471,999
12	To authorise the Directors to disapply pre-emption rights.	Special	121,465,547	100	0	0	121,465,547
13	To authorise the Company to purchase its own shares.	Special	121,471,999	100	0	0	121,471,999
14	To authorise calling of a general meeting on 14 clear days' notice.	Special	121,471,999	100	0	0	121,471,999

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

The Company's issued share capital is 469,466,512 ordinary shares of £0.001 each. Copies of the resolutions passed as special resolutions at the AGM will shortly be available for inspection at the National Storage Mechanism, which is located at: http://www.morningstar.co.uk/uk/nsm.

Enquiries:

Nuformix plc Dr Dan Gooding, Chief Executive Officer	+44 (0)1223 423667
Optimum Strategic Communications Mary Clark, Supriya Mathur Email: nuformix@optimumcomms.com	+44 (0) 203 950 9144

About Nuformix plc: www.nuformix.com 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. 

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGLLFSEADIILIA